HK1201753A1 - Treatment of cancer with tor kinase inhibitors tor - Google Patents
Treatment of cancer with tor kinase inhibitors torInfo
- Publication number
- HK1201753A1 HK1201753A1 HK15102409.4A HK15102409A HK1201753A1 HK 1201753 A1 HK1201753 A1 HK 1201753A1 HK 15102409 A HK15102409 A HK 15102409A HK 1201753 A1 HK1201753 A1 HK 1201753A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tor
- cancer
- treatment
- kinase inhibitors
- tor kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611374P | 2012-03-15 | 2012-03-15 | |
| US201261715331P | 2012-10-18 | 2012-10-18 | |
| PCT/US2013/031185 WO2013138553A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201753A1 true HK1201753A1 (en) | 2015-09-11 |
Family
ID=48014333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102409.4A HK1201753A1 (en) | 2012-03-15 | 2015-03-10 | Treatment of cancer with tor kinase inhibitors tor |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130245027A1 (xx) |
| EP (1) | EP2825169B1 (xx) |
| JP (2) | JP2015511963A (xx) |
| KR (1) | KR102057359B1 (xx) |
| CN (1) | CN104271139A (xx) |
| AU (1) | AU2013202993B2 (xx) |
| BR (1) | BR112014022707A2 (xx) |
| CA (1) | CA2867348A1 (xx) |
| ES (1) | ES2678250T3 (xx) |
| HK (1) | HK1201753A1 (xx) |
| IL (1) | IL234641B (xx) |
| MX (1) | MX360880B (xx) |
| MY (1) | MY178012A (xx) |
| NI (1) | NI201400112A (xx) |
| NZ (1) | NZ628407A (xx) |
| PH (1) | PH12014502046A1 (xx) |
| SG (1) | SG11201405724RA (xx) |
| TW (1) | TWI635862B (xx) |
| WO (1) | WO2013138553A1 (xx) |
| ZA (1) | ZA201406701B (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| WO2014172423A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| EP4218763A1 (en) | 2013-04-17 | 2023-08-02 | Signal Pharmaceuticals, LLC | 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| TWI631949B (zh) * | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| EP2986319A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| CN112933088B (zh) * | 2021-02-03 | 2022-02-22 | 南华大学附属第一医院 | Y041-5921在制备抗肿瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2631003T3 (es) | 2006-10-19 | 2017-08-25 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
| CA2666624C (en) * | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US20090258096A1 (en) * | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer Methods Employing Extracts of Gleditsia sinensis Lam |
| EP2320894B1 (en) * | 2008-08-20 | 2016-12-28 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chemoprevention of head and neck squamous cell carcinomas |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| EP2493472B1 (en) | 2009-10-26 | 2016-12-07 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
-
2013
- 2013-03-14 MY MYPI2014702602A patent/MY178012A/en unknown
- 2013-03-14 SG SG11201405724RA patent/SG11201405724RA/en unknown
- 2013-03-14 ES ES13713003.5T patent/ES2678250T3/es active Active
- 2013-03-14 MX MX2014011118A patent/MX360880B/es active IP Right Grant
- 2013-03-14 EP EP13713003.5A patent/EP2825169B1/en active Active
- 2013-03-14 NZ NZ628407A patent/NZ628407A/en not_active IP Right Cessation
- 2013-03-14 BR BR112014022707-1A patent/BR112014022707A2/pt not_active IP Right Cessation
- 2013-03-14 CA CA2867348A patent/CA2867348A1/en not_active Abandoned
- 2013-03-14 KR KR1020147028898A patent/KR102057359B1/ko active IP Right Grant
- 2013-03-14 TW TW102109151A patent/TWI635862B/zh active
- 2013-03-14 WO PCT/US2013/031185 patent/WO2013138553A1/en active Application Filing
- 2013-03-14 CN CN201380024241.3A patent/CN104271139A/zh active Pending
- 2013-03-14 US US13/803,305 patent/US20130245027A1/en not_active Abandoned
- 2013-03-14 AU AU2013202993A patent/AU2013202993B2/en not_active Ceased
- 2013-03-14 JP JP2015500593A patent/JP2015511963A/ja active Pending
-
2014
- 2014-09-12 ZA ZA2014/06701A patent/ZA201406701B/en unknown
- 2014-09-12 NI NI201400112A patent/NI201400112A/es unknown
- 2014-09-14 IL IL234641A patent/IL234641B/en active IP Right Grant
- 2014-09-15 PH PH12014502046A patent/PH12014502046A1/en unknown
-
2015
- 2015-03-10 HK HK15102409.4A patent/HK1201753A1/xx unknown
-
2017
- 2017-11-13 JP JP2017218014A patent/JP6470820B2/ja active Active
-
2022
- 2022-10-28 US US17/976,471 patent/US20230338370A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014502046B1 (en) | 2014-12-10 |
| JP6470820B2 (ja) | 2019-02-13 |
| EP2825169B1 (en) | 2018-05-09 |
| BR112014022707A2 (pt) | 2020-10-27 |
| CN104271139A (zh) | 2015-01-07 |
| NI201400112A (es) | 2015-01-15 |
| EP2825169A1 (en) | 2015-01-21 |
| WO2013138553A1 (en) | 2013-09-19 |
| TW201343165A (zh) | 2013-11-01 |
| ZA201406701B (en) | 2016-05-25 |
| MY178012A (en) | 2020-09-29 |
| US20230338370A1 (en) | 2023-10-26 |
| US20130245027A1 (en) | 2013-09-19 |
| CA2867348A1 (en) | 2013-09-19 |
| AU2013202993B2 (en) | 2015-09-03 |
| JP2015511963A (ja) | 2015-04-23 |
| SG11201405724RA (en) | 2014-10-30 |
| IL234641B (en) | 2020-04-30 |
| IL234641A0 (en) | 2014-11-30 |
| NZ628407A (en) | 2016-04-29 |
| MX2014011118A (es) | 2015-04-08 |
| KR102057359B1 (ko) | 2019-12-18 |
| TWI635862B (zh) | 2018-09-21 |
| AU2013202993A1 (en) | 2013-10-03 |
| ES2678250T3 (es) | 2018-08-09 |
| PH12014502046A1 (en) | 2014-12-10 |
| JP2018052963A (ja) | 2018-04-05 |
| MX360880B (es) | 2018-11-21 |
| KR20140138951A (ko) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1220640A1 (zh) | 用谷氨醯胺酶的雜環抑制劑治療癌症 | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (en) | Treatment of cancer | |
| HK1205500A1 (en) | Kinase inhibitors for the treatment of cancer | |
| EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
| GB201217890D0 (en) | Treatment of cancer | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors | |
| GB201208296D0 (en) | Treatment of cancer |